Vyome Holdings, Inc. (HIND) - Total Assets
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) holds total assets worth $9.18 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vyome Holdings, Inc. - Total Assets Trend (2003–2025)
This chart illustrates how Vyome Holdings, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see how much is Vyome Holdings, Inc. worth for the company's overall valuation and market capitalisation.
Vyome Holdings, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Vyome Holdings, Inc.'s total assets of $9.18 Million consist of 83.7% current assets and 16.3% non-current assets. Review HIND current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.7% |
| Accounts Receivable | $98.61K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $314.19K | 4.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Vyome Holdings, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Vyome Holdings, Inc. stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vyome Holdings, Inc.'s current assets represent 83.7% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 76.7% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is intangible assets at 4.8% of total assets.
Vyome Holdings, Inc. Competitors by Total Assets
Key competitors of Vyome Holdings, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Vyome Holdings, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.37 | 2.77 | 1.08 |
| Quick Ratio | 4.37 | 1.97 | 1.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.29 Million | $5.66 Million | $5.11 Million |
Vyome Holdings, Inc. - Advanced Valuation Insights
This section examines the relationship between Vyome Holdings, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.44 |
| Latest Market Cap to Assets Ratio | 2.12 |
| Asset Growth Rate (YoY) | 35.6% |
| Total Assets | $6.50 Million |
| Market Capitalization | $13.76 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vyome Holdings, Inc.'s assets at a significant premium (2.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vyome Holdings, Inc.'s assets grew by 35.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vyome Holdings, Inc. (2003–2025)
The table below shows the annual total assets of Vyome Holdings, Inc. from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.50 Million | +35.56% |
| 2024-12-31 | $4.79 Million | -55.32% |
| 2023-12-31 | $10.73 Million | -4.78% |
| 2022-12-31 | $11.27 Million | -78.56% |
| 2021-12-31 | $52.53 Million | +32.27% |
| 2020-12-31 | $39.71 Million | +0.15% |
| 2019-12-31 | $39.66 Million | -14.30% |
| 2018-12-31 | $46.27 Million | -47.84% |
| 2017-12-31 | $88.70 Million | +1159.84% |
| 2016-12-31 | $7.04 Million | -39.23% |
| 2015-12-31 | $11.59 Million | -19.46% |
| 2014-12-31 | $14.39 Million | -45.48% |
| 2013-12-31 | $26.39 Million | +1.12% |
| 2012-12-31 | $26.10 Million | -19.67% |
| 2011-12-31 | $32.49 Million | -16.03% |
| 2010-12-31 | $38.69 Million | +138.60% |
| 2009-12-31 | $16.21 Million | -42.66% |
| 2008-12-31 | $28.28 Million | -52.11% |
| 2007-12-31 | $59.05 Million | +63.74% |
| 2006-12-31 | $36.06 Million | +211.95% |
| 2005-12-31 | $11.56 Million | +1512.39% |
| 2003-12-31 | $717.00K | -- |
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinica… Read more